{"id":785866,"date":"2023-09-25T08:14:20","date_gmt":"2023-09-25T12:14:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\/"},"modified":"2023-09-25T08:14:20","modified_gmt":"2023-09-25T12:14:20","slug":"viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\/","title":{"rendered":"Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors"},"content":{"rendered":"

<\/p>\n

Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors<\/b><\/p>\n

– Dr. Gheuens is the Chief Medical Officer and Head of R&D of Agios Pharmaceuticals, Inc. –<\/i><\/p>\n

WALTHAM, Mass.–(BUSINESS WIRE<\/a>)–
\nViridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Sarah Gheuens, M.D., Ph.D., to its Board of Directors. Dr. Gheuens is the Chief Medical Officer (CMO) and Head of R&D of Agios Pharmaceuticals, Inc.<\/p>\n

\n\u201cSarah\u2019s extensive global clinical development and regulatory experience, including oversight of Phase 3 programs throughregulatory submissions and launch, will prove extraordinarily valuable as Viridian advances its late-stage candidates for the potential benefit of patients living with thyroid eye disease (TED),\u201d said Tomas Kiselak, Chairperson of the Viridian Therapeutics Board of Directors. \u201cWe\u2019re fortunate to be able to strengthen the Board with a physician-scientist of Sarah\u2019s caliber, and I very much look forward to working with her.\u201d<\/p>\n

\nDr. Gheuens joined Agios in 2019, was promoted to CMO in 2021, and assumed leadership of the R&D organization in 2022. During her time at Agios, she has overseen early- and late-stage clinical development globallyacross multiple indications, including pyruvate kinase deficiency, thalassemia, and sickle cell disease.<\/p>\n

\n\u201cI\u2019m thrilled to be joining the Board of an organization so clearly committed to addressing areas of high unmet medical need among patients affected by serious and rare diseases, particularly those in the complex autoimmune space,\u201d said Dr. Gheuens. \u201cI\u2019ve dedicated much of my career to developing medicines for underserved patient populations across a range of therapeutic areas. I\u2019m excited to leverage my experience to support the Viridian team as it focuses on delivering potentially first- and best-in-class therapies to change the treatment paradigm for TED.\u201d<\/p>\n

\nPrior to Agios, Dr. Gheuens held roles of increasing responsibility at Biogen in the areas of safety, medical affairs, and clinical development. Before transitioning to industry, she was a clinician at Boston\u2019s Beth Israel Deaconess Medical Center (BIDMC), taking care of patients with HIV and neurological complications while also researching progressive multifocal leukoencephalopathy. Dr. Gheuens received her medical degree from the Free University of Brussels (VUB), Belgium, and completed her neurology residency at the University Hospital of the Free University of Brussels, Belgium, followed by an HIV\/neurology fellowship at BIDMC. She also holds a Ph.D. in Medical Sciences from the University of Antwerp, Belgium, and a Master\u2019s in Medical Sciences from Harvard Medical School.<\/p>\n

About Viridian Therapeutics<\/b><\/p>\n

\nViridian Therapeutics is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian\u2019s expertise in antibody discovery and engineering enables it to develop differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.<\/p>\n

\nViridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting its first global Phase 3 trial called THRIVE to evaluate the safety and efficacy of VRDN-001 in patients with active TED. Viridian is also planning a second Phase 3 trial, called THRIVE-2, to evaluate the safety and efficacy of VRDN-001 in patients with chronic TED. In addition to its intravenously administered VRDN-001 program, the Company is advancing three candidates for its subcutaneous strategy with the goal of providing a more conveniently administered therapy to patients with TED. Viridian is developing multiple preclinical assets in autoimmune and rare diseases.<\/p>\n

\nViridian is based in Waltham, Massachusetts. For more information, please visit https:\/\/www.viridiantherapeutics.com<\/a>. Follow Viridian on LinkedIn<\/a> and Twitter<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230925962260\/en\/<\/a><\/span><\/p>\n

\nInvestors:
\n
Louisa Stone, 508-808-2400
\n
Manager, Investor Relations
\n
IR@viridiantherapeutics.com<\/a><\/p>\n

\nMedia:
\n
Matt Fearer, 617-272-4605
\n
Vice President, Corporate Communications
\n
Media@viridiantherapeutics.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health General Health Research Science Optical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors – Dr. Gheuens is the Chief Medical Officer and Head of R&D of Agios Pharmaceuticals, Inc. – WALTHAM, Mass.–(BUSINESS WIRE)– Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Sarah Gheuens, M.D., Ph.D., to its Board of Directors. Dr. Gheuens is the Chief Medical Officer (CMO) and Head of R&D of Agios Pharmaceuticals, Inc. \u201cSarah\u2019s extensive global clinical development and regulatory experience, including oversight of Phase 3 programs throughregulatory submissions and launch, will prove extraordinarily valuable as Viridian advances its late-stage candidates for the potential benefit of patients living with thyroid eye … <\/p>\n

Continue reading “Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-785866","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nViridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors – Dr. Gheuens is the Chief Medical Officer and Head of R&D of Agios Pharmaceuticals, Inc. – WALTHAM, Mass.–(BUSINESS WIRE)– Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Sarah Gheuens, M.D., Ph.D., to its Board of Directors. Dr. Gheuens is the Chief Medical Officer (CMO) and Head of R&D of Agios Pharmaceuticals, Inc. \u201cSarah\u2019s extensive global clinical development and regulatory experience, including oversight of Phase 3 programs throughregulatory submissions and launch, will prove extraordinarily valuable as Viridian advances its late-stage candidates for the potential benefit of patients living with thyroid eye … Continue reading "Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-25T12:14:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230925962260r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors\",\"datePublished\":\"2023-09-25T12:14:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\\\/\"},\"wordCount\":667,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230925962260r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\\\/\",\"name\":\"Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230925962260r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-09-25T12:14:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230925962260r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230925962260r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors - Market Newsdesk","og_description":"Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors – Dr. Gheuens is the Chief Medical Officer and Head of R&D of Agios Pharmaceuticals, Inc. – WALTHAM, Mass.–(BUSINESS WIRE)– Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Sarah Gheuens, M.D., Ph.D., to its Board of Directors. Dr. Gheuens is the Chief Medical Officer (CMO) and Head of R&D of Agios Pharmaceuticals, Inc. \u201cSarah\u2019s extensive global clinical development and regulatory experience, including oversight of Phase 3 programs throughregulatory submissions and launch, will prove extraordinarily valuable as Viridian advances its late-stage candidates for the potential benefit of patients living with thyroid eye … Continue reading \"Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-25T12:14:20+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230925962260r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors","datePublished":"2023-09-25T12:14:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\/"},"wordCount":667,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230925962260r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\/","name":"Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230925962260r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-09-25T12:14:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230925962260r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230925962260r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-appoints-sarah-gheuens-m-d-ph-d-to-its-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/785866","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=785866"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/785866\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=785866"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=785866"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=785866"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}